Truveta Announces Collaboration with Boston Scientific

September 27, 2022—Truveta announced a strategic collaborative agreement with Boston Scientific Corporation whereby Boston Scientific researchers will be able to access data from Truveta that contains deidentified medical records from more than 65 million patients in the United States.

According to Truveta, the collaboration seeks to improve long-term patient care and gain insights into health care disparities.

Truveta is a collective of 24 health systems that include 20,000 clinics and 700 hospitals across 43 states. These members provide deidentified data to Truveta daily. The data are licensed for health care research, not targeted advertising, noted the company.

Vascular medicine specialist Michael R. Jaff, DO, is Chief Medical Officer and Vice President, Medical Affairs, Innovation, and Technology, Peripheral Interventions, at Boston Scientific.

Dr. Jaff commented in the press release, “Truveta will enable us to gather insights on a breadth of devices and disease states, including peripheral artery disease (PAD), venous thromboembolic disease, and segments of interventional oncology.”

Dr. Jaff continued, “The first analysis will focus on gaining a deeper understanding of the long-term patient outcomes relating to the use of our products indicated for treatment of PAD and will enable us to further our commitment to addressing the disparities in access to healthcare that exist across various patient populations and demographics.”

Truveta advised that in conjunction with PAD Awareness Month, the company recently shared new insights from its deidentified data, including findings on more than 11,000 PAD patients who received revascularization procedures.

The company reported that the findings showed that Black or African American patients with PAD (1.0%) were less likely to undergo revascularization than white patients diagnosed with PAD (2.6%). Of those patients who are treated with an interventional procedure, Black or African American patients were also less likely to receive drug-eluting stents than white patients.

Insights into major adverse outcomes, like lower limb amputation, showed that patients treated with drug-eluting stents had lower rates (4.8%) of amputation compared to all patients who received revascularization (8.5%).

Truveta data provide an up-to-date picture of health in the United States across age, race, ethnicity, geography, socioeconomic factors, and more. Data are updated daily, deidentified, and aggregated. The data include the full Electronic Medical Record, including device-specific data as well as the medical bill from claims data.

These clinical data are linked across providers and with medical claims when care is provided outside Truveta’s network. Every patient record is enhanced with comprehensive socioeconomic data and daily mortality data for a complete picture of each patient’s health journey without risk of reidentification, stated the company.